StocksMediumUpdated•Originally published 6 November 2026•Updated 6 November 2026•
1 min read
Moderna Hikes 2026 Revenue Outlook on Overseas COVID Vaccine Demand
Key Facts
1Moderna raised its 2026 revenue growth outlook to a range of 15% to 25%, up from its previous guidance of up to 10%.
2The company significantly beat third-quarter revenue and earnings estimates as newer vaccines gained market traction.
Moderna raised its annual revenue growth outlook for 2026 to a range of 15% to 25%. CNBC reported that the upward revision from the previous 10% guidance was driven by strong demand for COVID vaccines in overseas markets and a significant beat on third-quarter earnings and revenue estimates.
MRNA closed at $241.46 on November 5, 2026, having traded between a session high of $261.00 and a low of $237.65. The improved long-term guidance follows robust international traction for the company's newer vaccine portfolio and stronger-than-expected global demand.